UnityPoint Health | 2019 Public Comments

2019 Public Comments

When relevant legislation, regulations, guidance, and other opportunities to shape policy related to health services research arise, UnityPoint Health may decide it is appropriate to develop an official position. The UnityPoint Health Government & External Affairs department serves as the primary liaison for regulatory submissions in response to state and federal rule-making and public requests for information, as well as communications advocating changes in state and federal policy direction or strategic initiatives.

Federal Comments

HIPAA and Coordinated Care

Agency: Department of Health and Human Services (HHS)

Request for Information (RFI) on Modifying HIPAA Rules to Improve Coordinated Care

Additional Information on HIPAA and Coordinated Care RFI

Health IT and Electronic Health Records (EHRs)

Agency: Office of the National Coordinator for Health Information Technology (ONC)

Draft Strategy on Reducing Regulatory and Administrative Burden relating to the Use of Health IT and EHRs

Additional Information on the Draft Health IT and EHR Strategy

Medicare Part D Drug Prices 

Agency: Centers for Medicare & Medicaid Services (CMS)

Proposed Changes to Modernize Part D and Medicare Advantage to Lower Drug Prices and Reduce Out of Pocket Expenses

Additional Information on the Proposed Rule on Medicare Part D

Healthy People 2030 Objectives 

Agency: Health and Human Services (HHS)

Proposed Core, Developmental and Research Objectives for Healthy People 2030

Additional Information on Healthy People 2030 Objectives

Medicaid Managed Care

Agency: Centers for Medicare & Medicaid Services (CMS)

Proposed Changes to the Medicaid Program; Medicaid and Children's Health Insurance Plan (CHIP) Managed Care 

Additional Information on the Proposed Rule on Medicaid Managed Care

State Comments

Iowa Prescription Monitoring Program – ARC 4205C

Agency: Iowa Board of Pharmacy

Revisions to the Iowa Prescription Monitoring Program, including the Role of Hospital Pharmacies 

Additional Information on the Notice of Intended Action on the Iowa Prescription Monitoring Program

Legislative Positions and Collaborative Sign-On Letters

There are no comments yet available.

For Further Information:

Please email Cathy Simmons, Executive Director of Regulatory Affairs.